Apheresis Market Report by Component (Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or Leukopheresis), Lymphocytes (Lymphopheresis or Lymphapheresis), RBC's (Erythropheresis)), Product (Devices, Disposables and Reagents, Software), Technology (Centrifugation, Membrane Separation, Selective Adsorption), Procedure (Donor/Automated Apheresis, Therapeutic Apheresis), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Others), End User (Blood Centers, Hospitals, and Others), and Region 2024-2032
The global apheresis market size reached US$ 2.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.59% during 2024-2032.
Apheresis is a procedure of separating donated blood components, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma, to treat various diseases. It assists in treating sickle cell disease wherein red blood cells (RBCs) are shaped abnormally and cannot carry oxygen through the body. It is also employed to remove abnormal white blood cells (WBCs) that thicken the blood and interfere with organ function. In addition, as it aids in treating blood cancers and blood disorders, such as myasthenia gravis and thrombotic thrombocytopenic purpura (TTP), apheresis is widely used in blood collection centers, hospitals, and ambulatory centers across the globe.
Apheresis Market Trends:
The growing demand for apheresis to treat various diseases, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, represents one of the key factors driving the market. Besides this, there is a rise in the utilization of apheresis to collect plasma for treating burnt and trauma patients across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, increasing investments by key market players in research and development (R&D) activities to introduce an enhanced blood purification device that treats severe forms of arteriosclerosis obliterans is positively influencing the market. In addition, the rising demand for source plasma to treat primary immunodeficiency and hemophilia is offering lucrative growth opportunities to industry investors. Apart from this, the growing employment of apheresis as a therapy for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure, is offering a positive market outlook. Additionally, the increasing awareness among the masses about the benefits of apheresis is bolstering the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global apheresis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on component, product, technology, procedure, application and end user.
Breakup by Component:
Plasma (Plasmapheresis)
Platelets (Plateletpheresis)
Leukocytes (Leukapheresis or Leukopheresis)
Lymphocytes (Lymphopheresis or Lymphapheresis)
RBC's (Erythropheresis)
Breakup by Product:
Devices
Disposables and Reagents
Software
Breakup by Technology:
Centrifugation
Membrane Separation
Selective Adsorption
Breakup by Procedure:
Donor/Automated Apheresis
Therapeutic Apheresis
Breakup by Application:
Renal Disorders
Hematological Disorders
Neurological Disorders
Autoimmune Disorders
Others
Breakup by End User:
Blood Centers
Hospitals
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation).
Key Questions Answered in This Report
1. What was the size of the global apheresis market in 2023?
2. What is the expected growth rate of the global apheresis market during 2024-2032?
3. What are the key factors driving the global apheresis market?
4. What has been the impact of COVID-19 on the global apheresis market?
5. What is the breakup of the global apheresis market based on the component?
6. What is the breakup of the global apheresis market based on the product?
7. What is the breakup of the global apheresis market based on the technology?
8. What is the breakup of the global apheresis market based on procedure?
9. What is the breakup of the global apheresis market based on the application?
10. What is the breakup of the global apheresis market based on the end user?
11. What are the key regions in the global apheresis market?
12. Who are the key players/companies in the global apheresis market?